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Abstract
Chronic damage and repair of the bronchial epithelium are features of asthma. We have previously reported that ex vivo
stimulation of normal bronchial epithelial cells with epidermal growth factor (EGF), a key factor of epithelial repair, enhances
the mechanisms of neutrophil accumulation, thereby promoting neutrophil defences during acute injury but potentially
enhancing inflammation in chronic airway diseases. We have now sought to (i) determine whether this EGF-dependent pro-
neutrophil activity is increased in asthma, where EGF and its epithelial receptor are over-expressed, and (ii) elucidate some
of the mechanisms underlying this asthmatic epithelial-neutrophil interaction. Primary bronchial epithelial cells (PBEC) from
healthy subjects, mild asthmatics and moderate-to-severe asthmatics (Mod/Sev) were stimulated with EGF, a model that
mimics a repairing epithelium. Conditioned culture media (EGF-CM) were assessed for neutrophil chemotactic and anti-
apoptotic activities and inflammatory mediator production. EGF induced the epithelium to produce soluble mediators with
neutrophil chemotactic (p,0.001) and pro-survival (p = 0.021) activities which were related to the clinical severity of asthma
(trend p= 0.010 and p= 0.009, respectively). This was associated with enhanced IL-6, IL-8, GM-CSF and TNF-a release, and
cytokine-neutralising experiments using EGF-CM from Mod/Sev asthmatics demonstrated a role for GM-CSF in neutrophil
survival (p,0.001). Pre-treatment of neutrophils with specific inhibitors of the myeloid-restricted class I phosphatidylino-
sitol-3-OH kinase (PI(3)K) isoforms showed that neutrophil chemotaxis induced by EGF-CM from Mod/Sev asthmatics
depended on the c (p,0.021) but not d isoforms, while neutrophil survival required multiple class I PI(3)Ks. The EGF-induced
chemotactic, but not pro-survival activity, involved RhoA signaling in neutrophils (p = 0.012). EGF whose activity is
upregulated in asthma induces ex vivo the epithelium from asthmatic patients to produce pro-neutrophil activities; these
are related to asthma severity and, in moderate-to-severe asthmatics, involves class IB PI(3)Kc signaling, providing a
potential therapeutic target for neutrophilic forms of asthma.
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Introduction
Neutrophilic airway inflammation is a common feature of
severe chronic asthma [1,2,3,4] shown to be insensitive to
glucocorticoids (GCs) [5,6], but the mechanisms which regulate
the accumulation of neutrophils within the inflamed airways are
still poorly understood. Several studies in asthma have reported
raised concentrations of factors in the airways that have the
potential to chemoattract neutrophils and inhibit their apoptosis
including, interleukin (IL)-8 [3,7], IL-6 [8,9,10], granulocyte-
macrophage colony-stimulating-factor (GM-CSF) [8,9] and tu-
mour necrosis factor (TNF)-a [11,12]. A clear link between raised
levels of these factors and enhanced neutrophil chemotactic and
anti-apoptotic activity in asthma has yet to be established.
Delayed apoptosis, which is responsible for increased neutrophil
longevity in tissues is thought to impede the resolution of airway
inflammation [13]. We have recently detected significant neutro-
phil anti-apoptotic activity in the epithelial lining fluid of severe
asthmatic patients with sputum neutrophilia in whom far fewer
apoptotic neutrophils were observed [4], but have been unable to
identify the responsible factor (s). In an earlier study using the
bronchial 16HBE cell line and primary bronchial epithelial cells
(PBECs) from healthy individuals, we showed that ex vivo the
bronchial epithelium produces an array of neutrophil chemotactic
factors, IL-8, GM-CSF, TNF-a and LTB4 [14]. In the same study,
we also showed that epidermal growth factor (EGF), an important
factor of epithelial repair, enhanced the ex vivo production of these
chemotactic factors by the epithelium. In addition to regulating
airway mucosal injury and repair responses, EGF has also been
shown to contribute to airway wall remodeling [15], lung
inflammation [15,16,17] and airway dysfunction in a chronic
mouse model of allergic lung inflammation [18]. Over-expression
of EGF receptor (EGFR) and its ligands (i.e. EGF, amphiregulin,
heparin-binding EGF-like growth factor) has been observed in the
airways of adult [19,20,21,22] as well as paediatric asthmatics
[23,24], with levels of EGF and amphiregulin being significantly
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elevated following acute exacerbations in the latter patient
population [25,26]. This suggests that the pathobiology of asthma
involves and may in fact result, in part, from EGFR-mediated
dysregulation of injury-repair responses in the airway mucosa.
Consistent with this concept, immunostaining for the tyrosine-
kinase linked EGFR is increased in the asthmatic bronchial
epithelium in relation to disease severity and correlates with IL-8
expression and neutrophil numbers [17]. Ex vivo stimulation of
airway epithelial cells with EGF induces production of IL-8
[14,17,27] and this response is insensitive to GCs in airway
epithelial cells from asthmatics [17,28]. Together with the recent
identification of functional variants in genes linking epithelial
damage to the adaptive immune system [29], these studies point to
an important role for the airway epithelium in the pathogenesis of
asthma [15]. However, a direct link between the observed effects
of EGF on endogenous mediator production by the epithelium
and neutrophil accumulation has not been established, nor is there
evidence that this is a feature of clinical asthma.
In the current study, we tested the hypothesis that EGF plays an
important role in activating the bronchial epithelium of asthmatic
patients by up-regulating the release of mediators that recruit
neutrophils and/or inhibit their apoptosis in the airways. We also
hypothesised that this pro-neutrophilic activity increases in
relation to the clinical severity of asthma and thus provides a
potential mechanism for the unresolved airway neutrophilia
observed in more severe forms of this disease. To test this concept,
we applied our translational ex vivo model which uses primary
epithelial cell (PBEC) culture established from bronchoscopic
brushings of control subjects and asthmatic patients [19,30]. Cells
were either left in culture unstimulated or exposed to EGF, thus
mimicking an in vivo situation where the asthmatic epithelium
sustains injury and this is followed by repair, features that are
central to the pathogenesis of asthma. Using the conditioned
media (CM) from these cultures to assess their effects on neutrophil
chemotaxis and survival, we sought to determine whether, as part
of an acute insult, such as virus infection, associated with ,80% of
asthma exacerbations in paediatrics [31], or a chronic injury-
repair process, EGF can activate the asthmatic epithelium in a way
that modulates neutrophilic inflammatory responses and whether
this is related to asthma severity. Finally, in order to improve
understanding of the signaling pathways in neutrophils responding
to stimuli from an EGF-activated epithelium, we studied the effect
of inhibiting phosphatidylinositol-3-OH kinase (PI(3)K) signaling
on any induced neutrophil activity, focusing on the myeloid-
restricted class I PI(3)K isoforms, c and d [32]. Despite convincing
preclinical evidence that these PI(3)Ks are involved in driving
neutrophilic and allergic-type pulmonary inflammation in vivo
[33,34,35,36], little is known about how these kinases and their
downstream signaling in neutrophils are regulated by epithelium-
derived mediators in the context of clinical asthma.
Methods
Subjects
Twenty-eight non-smoking adult volunteers (8 steroid-naı¨ve
mild asthmatics (MA), 11 moderate-to-severe asthmatics (Mod/
Sev) and 9 non-atopic healthy control subjects (HC)) took part in
the study (see Table 1). Subjects with mild asthma had symptoms
.2 times/week, with forced expiratory volume in 1 sec (FEV1)
.80% of predicted and used short-acting inhaled b2-agonists as
needed for symptom relief. Subjects with moderate asthma were
treated with low-dose inhaled GCs and prn inhaled short-acting
b2-agonists. Subjects with severe asthma were taking regular oral
or high-dose inhaled GCs and a long-acting inhaled b2-agonist,
but despite that had FEV1 ,80% of predicted. The moderate and
severe asthmatics were analysed as one group (Mod/Sev). The
definition of asthma severity was in keeping with Global Initiative
for Asthma (GINA) 2010 criteria http://www.ginasthma.org (s.1).
Atopy was assessed by skin prick tests for common allergens. The
age-matched healthy controls were non-atopic, had no history of
smoking or respiratory symptoms suggestive of asthma and all had
FEV1 .90% of predicted.
The study was approved by the South and West Local Research
Ethics Committee, Southampton, U.K. and all subjects gave their
full informed written consent in accordance with the Declaration
of Helsinki.
Sampling and culture of primary bronchial epithelial cells
Primary bronchial epithelial cells were obtained by gentle
brushing of the third to fourth generation bronchi during
fibreoptic bronchoscopy as previously described [14,30]. The
epithelial cell were cultured in hormonally supplemented bron-
chial epithelial growth medium (BEGM) (Clonetics, San Diego,
CA, USA) in collagen-coated tissue culture flasks (Gibco-BRL,
Paisley, UK) at 37uC in 5% (v/v) CO2. At passage 2,
approximately 46105 cells/well were seeded into 24-well culture
plates and grown to 70% confluency. Cells were first rendered
quiescent for 24 h in serum-free medium (SFM) consisting of
BEBM basal medium (Clonetics, USA), supplemented with 1% (v/
v) insulin/transferrin/sodium selenite (Sigma, Poole, UK) and
0.3% (v/v) bovine serum albumin (BSA) and were then cultured
further for 24 h in SFM containing EGF (10 ng/ml) or SFM
alone. This generated EGF-conditioned media (EGF-CM) and
basal-conditioned media (basal-CM), respectively.
Analysis of bronchial-epithelial-derived mediators
Basal-CM and EGF-CM from all 3 subject groups were
analysed for IL-6, IL-8, TNF-a and GM-CSF using a combination
of Luminex-based multiplex assays (Bio-Rad) and ELISA (R&D
systems) according to manufacturer’s instructions.
Assessment of bronchial epithelial cell proliferation
Epithelial cell number was determined by uptake of methylene
blue [37]. Subconfluent epithelial cells were seeded into 24-well
plates at 2.56104 cells/well in complete BEGM medium and
allowed to adhere at 37uC. After 6 h, the medium was changed to
SFM, serum starved overnight, and then stimulated with SFM or
EGF (10 ng/ml) for 24 h. Monolayers were fixed with 4%
formaldehyde in 0.9% NaCl solution (20uC for 1 h) and stained
with 1% methylene blue in 10 mM disodium tetraborate (pH 8.5)
for 30 min and then washed again. Bound methylene blue was
eluted with 1% HCl in ethanol and cell number determined by
measuring the absorbance at 650 nm (A650) with a microplate
spectrophotometer (MultiScan Ascent, Affinity Sensors, Cam-
bridge, UK). A650 was directly proportional to the epithelial cell
number over the range of cell densities. The stimulation index was
calculated by dividing the mean number of epithelial cells exposed
to EGF (10 ng/ml, 24 h) by the mean number of cells incubated
with SFM alone.
Isolation of neutrophils from healthy human volunteers
Neutrophils were purified from peripheral blood by dextran
sedimentation and centrifugation through plasma/Percoll gradi-
ents as previously described [14]. All neutrophil donors were
healthy and non-atopic so as to avoid eosinophils whose numbers
may be raised in atopic/asthmatic patients. Isolated neutrophils
were routinely .96% pure and .98% viable as assessed by
EGF Mediates Epithelial-PMN Crosstalk in Asthma
PLOS ONE | www.plosone.org 2 September 2013 | Volume 8 | Issue 9 | e72502
cytospin and trypan blue exclusion, respectively. Endotoxin-free
reagents were used throughout to prevent inadvertent neutrophil
priming.
Assessment of neutrophil chemotaxis
The chemotactic activity of basal-CM or EGF-CM on
neutrophil migration was measured in a fluorescence-based
Neuroprobe ChemoTX microplate as described [14]. Briefly,
the lower wells of the microplate were filled with either 31 ml of
SFM, basal-CM or EGF-CM. Calcein-labeled neutrophils (36105
cells/ml) were loaded to the upper aspect of the membrane and
allowed to migrate for 60 min (37uC in 5% CO2). After washing,
transmigrated neutrophils were quantified by measuring fluores-
cence (485 nm excitation, 530 nm emission wavelengths) using a
fluorescence plate reader.
Analysis of neutrophil apoptosis
Purified neutrophils (56106 cells/ml) were incubated in CM for
20 h after which apoptosis was assessed by flow cytometry
(FACSCalibur, BD Biosciences) using fluorescein isothiocyanate-
labelled Annexin-V binding and propidium iodide (Annexin-
VFITC/PI) staining. Ten thousand gated events were acquired for
each sample and neutrophil apoptosis was expressed as a percentage
of apoptotic cells in relation to the total number of counted
neutrophils. This method was previously validated by comparison
with the gold standard microscopic method which assesses
neutrophil apoptosis using nucleus morphological criteria [4,38].
Further details of the experimental methods are provided in
File S1.
Statistics
Data were assessed for normality and where appropriate
presented as mean 6 SEM. The difference across three or more
groups (of independent experiments) was investigated using one-
way analysis of variance (ANOVA). Comparisons made within a
participant sample were analysed using a paired Student t-test for
two groups or a repeated one-way ANOVA when there were three
or more groups. When the results from the ANOVA analysis
suggested evidence of a difference in mean values (p,0.05) post
hoc tests, using Bonferroni adjustment to correct for multiple
comparisons, were performed to determine where these differenc-
es lay. Trend across the subject groups (severity of asthma) was
assessed by linear trend (regression) analysis. For data that were
not normally distributed, pair-wise comparisons were made using
the Mann-Whitney test whereas the Kruskal-Wallis test was
performed to determine if there were significant differences
between three or more groups. Trend across the subject groups
was assessed using the Cuzick’s non-parametric test. Analyses were
performed using Stata version 11 (StataCorp) graphs were
constructed using Prism (GraphPad). A p value ,0.05 was
considered significant.
Results
Pilot experiments to establish the bronchial epithelial
culture ex vivo model
Assessment of epithelial cell proliferation. In order to
assess whether any observed effects of EGF-activated PBECs on
neutrophil chemotaxis or anti-apoptotic survival are due to an
increase in the numbers or activity of existing epithelial cells
following EGF stimulation, an assessment of proliferation of
PBECs exposed to EGF was first performed using a colorimetric
assay based on methylene blue uptake and release (see File S1).
This showed that epithelial cell numbers were unchanged by EGF
stimulation for 24 h when compared with SFM alone, implying
that any observed changes in pro-neutrophil activity induced by
EGF would be due to increased secretory activity of non-
proliferating epithelial cells (Figure 1A).
Selection of dilution of PBEC conditioned medium for use
in neutrophil experiments. Chemotactic dose-responses are
usually bell-shaped and before proceeding with the full analysis of
PBEC conditioned media, pilot experiments were conducted to
assess whether the chemotactic responses were optimal to neat
EGF-CM or 1:2 and 1:5 dilutions thereof. This showed that
maximum chemotactic responses were observed with neat CM
(Figure 1B). Thus, neat CM samples were used in all subsequent
experiments.
Assessment of pro-neutrophil activity in PBEC cultures
from asthmatic and control subjects
Having validated the model for PBECs, we proceeded to assess
the chemotactic and neutrophil survival-enhancing activities in the
CM from PBECs derived from the three subject groups (HC, MA
and Mod/Sev). Unstimulated PBECs produced increased neutro-
phil chemotactic activity (as measured in basal-CM) in MA
subjects which was greater than the chemotactic responses to SFM
alone (ANOVA p=0.007; Bonferroni post-hoc test p= 0.299 in
HC, 0.004 in MA and 0.080 in Mod/Sev asthma, Figure 2A). By
comparison with SFM, EGF-CM contained significantly higher
chemotactic activity in all subject groups (ANOVA p,0.001, with
Bonferroni post-hoc test p values of 0.036 for HC and ,0.001 for
both MA and Mod/Sev asthmatics). In HC and Mod/Sev, but not
Table 1. Demographic and clinical characteristics of non-smoking patients with asthma and non-atopic healthy controls.
Healthy Controls (n=9) Mild Asthmatics (n=8) Moderate/Severe Asthmatics (n= 11)
Age (yr) 43.6766.10 36.5064.52 42.5565.02
Gender (M/F) 5/4 4/4 8/3
Atopy, n None 8 11
FEV1 (% predicted) 106.9663.29 87.0264.73
{{ 92.5366.52
Postbronchodilator FEV1 (L) 3.4960.32 3.0560.11 3.3160.29
ICS dose (mg/d) None None 431.82690.52
b2 agonist dose (mg/d) None 175.0616.37 163.64640.50
Data are expressed as mean 6 SEM and statistical significance by unpaired t-test, {{p,0.01 versus MA and HC; one-way ANOVA with post-hoc test and Bonferroni
correction (p = 0.05).
doi:10.1371/journal.pone.0072502.t001
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the MA subjects, stimulation of PBECs with EGF enhanced the
chemotactic activity when compared to basal-CM (p= 0.021 in
HC, 0.093 in MA and 0.010 in Mod/Sev asthma, Table S1); the
EGF-CM activity was related to clinical asthma severity as shown
by an increasing trend (linear contrast test p = 0.010) (Figure 2A).
A total of 60.31 6 6.88% (range 42.35–80.51%) of the
neutrophils underwent constitutive (spontaneous) apoptosis in
culture medium by 20 h. Basal and EGF-CM from all the PBEC
cultures from asthmatic, but not from healthy control subjects,
contained augmented neutrophil survival activity as shown by the
reduced spontaneous apoptosis of neutrophils in culture in CM
when compared to SFM (ANOVA p=0.041; Bonferroni post-hoc
p values of 0.603 for HC, 0.047 for MA and p= 0.014 for Mod/
Sev) (Figure 2B). The anti-apoptotic activity also showed an
increasing trend with asthma severity (linear contrast tests, basal-
CM p=0.046 and EGF-CM p=0.009) (Figure 2B), as observed
previously with airway epithelial lining fluid (sampled by sputum
induction) from severe asthmatics [4], but there was no additional
EGF-induced effect when compared to anti-apoptotic responses
mediated by unstimulated PBECs (Table S1).
EGF induces production of cytokines/chemokines in
PBEC cultures
The CM were analysed for production of pro-neutrophil factors
IL-6, IL-8, GM-CSF and TNF-a by PBECs. Analysis of basal-CM
and EGF-CM showed no differences between the subject groups
and there was no linear trend. While IL-8, GM-CSF and TNF-a
were induced by EGF in PBECs in all subject groups (Figure 3A-
D), IL-6 was induced significantly only in Mod/Sev asthmatics
(Figure 3A). While significant induction of all four mediators was
seen in Mod/Sev subjects and three of four mediators were
induced in MA subjects, in the HC subjects only two mediators
were induced significantly (Figure 3C and D). In contrast, the
concentrations of the lymphotactic chemokines, TARC/CCL17
and MDC/CCL22 were undetectable or low in most samples in
all three subject groups (data not shown).
Characterization of chemotactic and anti-apoptotic
activity in PBEC-CM derived from moderate to severe
asthma patients
Having observed clearly augmented pro-inflammatory mediator
responses to EGF-stimulation of PBECs from patients with Mod/
Sev asthma, their relative roles were analysed using neutralising
monoclonal antibodies (mAb) against GM-CSF and TNF-a and
IL-6R (for neutrophil survival) and the selective antagonist for the
CXCR2 receptor, SB-225002 (for neutrophil chemotaxis) at
concentrations validated previously [14]. This showed that the
neutrophil chemotactic activity in basal-CM or EGF-CM could
not be inhibited by any of these blocking agents (Figure 4A). In
contrast, anti-GM-CSF mAb, applied alone or together with either
anti-TNF-a or anti-IL-6R mAbs, blocked the pro-survival effects
of both basal-CM (repeated one-way ANOVA compared to
untreated basal-CM p,0.001) and EGF-CM (repeated one-way
ANOVA compared with untreated EGF-CM p,0.001; for p
values for individual blocking agents see Figure 4B). This suggested
that GM-CSF is an important regulator of neutrophil survival in
Mod/Sev asthmatic PBECs.
Activation of class I PI(3)Ks and downstream signaling in
neutrophils
We next studied whether activation of the myeloid-restricted
class I PI(3)K isoforms, c and d which regulate fundamental
cellular processes in neutrophils [39,40,41,42] are involved in the
regulation of chemotaxis induced by PBEC-CM from Mod/Sev
asthmatics by applying each of the PI(3)K inhibitors at maximally
effective concentrations [42]. Pre-treatment of neutrophils with the
broad spectrum PI(3)K inhibitor, wortmannin, before exposure to
basal-CM or EGF-CM blocked the neutrophil migration response
(Mann-Whitney test p= 0.011 and p= 0.001, respectively)
(Figure 5A). The PI(3)Kc-selective inhibitor, AS-252424 reduced
basal-CM–mediated chemotaxis (Mann-Whitney test p= 0.064)
and significantly blocked the migratory response towards EGF-
CM by 62.91% 67.55% (Mann-Whitney test p = 0.021). In
contrast, the PI(3)Kd-selective inhibitor, IC87114 displayed no
inhibitory effects (see Figure S1, in File S1), suggesting that
PI(3)Kd is not required to drive neutrophil chemotaxis in response
to the generated mediators in PBEC-CM.
LY294002, a non-selective class I PI(3)K inhibitor with a longer
half-life in culture than wortmannin was tested in neutrophil
apoptosis assays in vitro. Epithelium–mediated neutrophil survival
was wholly PI(3)K-dependent as seen by the complete reversal by
Figure 1. Effects of EGF on primary bronchial epithelial cell
(PBEC) proliferation and mediating neutrophil chemotaxis. (A)
PBECs were exposed to EGF and proliferation was assessed using a
colorimetric assay based on methylene blue uptake and release (see
Results section; pilot experiments). The stimulation index derived by
dividing the methylene blue uptake of cells exposed to EGF (10 ng/ml,
24 h) by the uptake of unexposed cells were ,1 in all subject groups,
suggesting that, EGF did not increase the numbers of epithelial cells
(n=3–5 donors from each group). (B) Dose-dependency of chemotactic
responses to PBEC conditioned media. PBECs were stimulated with EGF
(10 ng/ml) to generate EGF-CM or left untreated (Basal-CM). Neutrophil
chemotaxis induced by the CM was compared to SFM as described in
Methods. The chemotactic activity was concentration-dependent with a
maximal effect observed when using neat CM (n=3 donors).
doi:10.1371/journal.pone.0072502.g001
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LY294002 of the anti-apoptotic effects induced by both basal-CM
and EGF-CM from Mod/Sev asthmatics (both ANOVAs,
p,0.001, Figure 5B). In contrast, the regulation of the pro-
survival effects were not isoform-specific for either PI(3)K d or c as
their respective isoform-selective inhibitors, IC87114 and AS-
252424 both partially (yet significantly, post-hoc test p = 0.003 and
p= 0.005 for basal-CM; p= 0.008 and p= 0.001 for EGF-CM,
respectively) reduced the effects of basal-CM and EGF-CM on
neutrophil apoptosis in a functionally redundant manner
(Figure 5B). None of the PI(3)K inhibitors significantly affected
constitutive neutrophil apoptosis, suggesting that the isolated
neutrophils were in culture in an unprimed state.
We next investigated the regulatory role of RhoA GTPase on
chemotaxis and pro-survival signaling mediated by PBEC-CM
from Mod/Sev asthma patients. Treatment of neutrophils with the
3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase
inhibitor, mevastatin (50 mM, a published concentration, see
Figure S2, File S1) diminished both basal-CM and EGF-CM–
initiated chemoattraction from Mod/Sev PBECs (one-way
ANOVA, p= 0.015 and p= 0.001; post hoc test, p = 0.047 and
p= 0.012, respectively) (Figure 6A), suggesting potential coupling
of the RhoA GTPase to neutrophil chemotactic responses. In
contrast, pretreatment of neutrophils with mevastatin had a
modest, but significant (paired t-test, p = 0.038, Figure 6B), effect
on EGF-CM–induced anti-apoptotic activity, suggesting that
neutrophil survival partially depends on RhoA signaling.
Discussion
Employing an ex vivo model to study bronchial epithelial cell
responses in asthmatics, the current study has made two novel
important observations. First, EGF induced the production of pro-
inflammatory mediators by epithelial cells from moderate to severe
asthmatics that increased the chemotaxis and prolonged the
survival of neutrophils. This pro-inflammatory activity was
upregulated with increasing severity of asthma, pointing to an
aberrant asthmatic bronchial epithelium as a potentially important
source and further confirming its important role in promoting
elevated neutrophil pro-survival activity detected in the airway
epithelial lining fluid (induced sputum) in a subset of severe
asthmatics with airway neutrophilia [4]. The second novelty
comes from the observation that the epithelium acts on neutrophils
via class I PI(3)K signaling. While the neutrophil migratory
responses required class IB PI(3)Kc signaling, the anti-apoptotic
activity was dependent on multiple class I PI(3)Ks, suggesting
differential regulation of these two mechanisms of cell accumula-
tion. Although the current study was unable to identify any of the
studied chemotactic candidates mediating neutrophil migration,
the induced neutrophil survival response could be attributed to a
significant extent to GM-CSF, a cytokine that is known to extend
neutrophil longevity by delaying constitutive apoptosis [43,44]. A
summary of the potential interactions between neutrophils and an
EGF-conditioned airway epithelium in enhancing neutrophil
chemotaxis and pro-survival responses in asthma is provided in
Figure S2 in File S1.
While previous studies have demonstrated that bronchial
epithelial cells from normal and asthmatic donors generate pro-
inflammatory mediators ex vivo that can influence neutrophil
functional responses [14,17,43,45], this study provides the first
evidence that an EGF-induced airway epithelium can upregulate
neutrophil accumulation in relation to asthma severity in a
PI(3)Kc dependent fashion. Using samples from relevant patient
populations, the present translational findings provide a novel
mechanistic perspective for neutrophilic mucosal inflammation
that underpins the pathobiology of more severe phenotypes of
asthma.
While both normal and asthmatic epithelia showed an ability to
regulate neutrophil function, this was most pronounced in
epithelium derived from asthmatic patients and following activa-
tion with EGF. Stimulation of PBECs from asthmatic patients with
EGF induced significant up-regulation of such pro-neutrophilic
factors as IL-6, IL-8, GM-CSF and TNF-a. This was seen in both
MA and Mod/Sev patients except for IL-6 which was not
upregulated in MA by EGF. The fact that only two of the four
Figure 2. Neutrophil chemotactic and anti-apoptotic activity generated by EGF-induced bronchial epithelial cells. Conditioned media
(CM) from 9 healthy control subjects, 8 mild and 11 Mod/Sev asthmatics were assessed for neutrophil chemotactic and anti-apoptotic activity as
described in Methods. (A) Neutrophil chemotaxis was significantly induced by stimulation of PBECs with EGF in HC (p = 0.021) and Mod/Sev asthma
(p = 0.010) but not in MA (0.093). The chemotactic activity in EGF-CM was related to the clinical severity of asthma (linear contrast test p = 0.010) (n=8
donors). (B) Neutrophil apoptosis was assessed after 20 h of culture by FACS analysis of Annexin-VFITC/PI staining and both basal and EGF-CM from
the asthma-derived PBECs, but not from HC, contained significant neutrophil anti-apoptotic activity when compared to SFM (MA, p= 0.047 and Mod/
Sev, p = 0.014; HC, p = 0.603, respectively). The anti-apoptotic activity in basal-CM and EGF-CM increased in relation to disease severity (p = 0.046 and
0.009, respectively, as assessed by trend analysis), (n=7 donors). Repeated one-way ANOVA with post-hoc Bonferroni; {p,0.05, {{p,0.01 and
{{{p,0.001 compared to SFM-treated neutrophils. *p,0.05 vs. basal-CM.
doi:10.1371/journal.pone.0072502.g002
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cytokines measured were upregulated in cultures from healthy
subjects suggests a trend for EGF effects to be more pronounced in
disease, especially in more severe asthma. Cytokine-neutralising
experiments in Mod/Sev disease showed GM-CSF to be a
contributor to the anti-apoptotic activity generated by EGF. This
is consistent with enhanced GM-CSF levels observed in asthma-
derived PBECs triggered by other relevant stimuli, such as
mechanical wounding, pollutants and respiratory viruses
[46,47,48].
In the current study, we also sought evidence for TARC/CCL17
and MDC/CCL22, two lymphotactic chemokines that are impli-
cated in the recruitment of T lymphocytes and eosinophils, but these
were either undetectable or low in most CM in all three subject
groups. This suggests that the airway mucosa stimulated by EGF
during epithelial injury and repair is likely to favour the pro-
inflammatory potential of neutrophils rather than lymphocytes in
the airways of more severe asthmatics. Furthermore, the biosyn-
thetic capacity of the asthmatic PBECs to secrete these neutrophil-
active factors remained preserved in culture even after the second
passage ex vivo, reflecting an intrinsic secretory phenotype that exists
in vivo. The evidence available from this and our previous study of
primary human bronchial epithelial cells [14] suggests that EGF
modulates the function of neutrophils via its action on the epithelium
and not through a direct effect on neutrophils. The role of other
EGFR ligands in relation to neutrophil function is unclear and will
need to be elucidated; previous studies have shown that one of the
EGFR ligands (HB-EGF) decreases neutrophil-endothelial interac-
tions and can also block the generation of superoxide anions from
human neutrophils [49,50,51].
We have previously shown that the asthmatic epithelium
contains areas of exposed basal cells expressing EGFR on the
luminal surface [19]. Our ex vivo model aimed to mimic activation
of these cells in vivo by EGFR ligands present in the mucosal lining
fluid. While others have used a scrape-wound model to examine
responses in differentiated airway epithelial cells [52], such models
are time-consuming and difficult to control (e.g. total versus partial
thickness damage, size of the wound, basal activities of EGF etc).
Our disease-related model provides a simple alternative that allows
study of patient-derived epithelial cells with a basal cell phenotype
and evaluation of mucosal inflammatory responses to such factors
as EGF. Whilst the use of undifferentiated bronchial epithelial cells
might also be seen as a limitation of the current study, this
phenotype is appropriate for the aims of this study since it reflects
an injured/repairing airway epithelium present in asthmatics in
vivo [19]. Nevertheless, additional studies using differentiated
primary epithelial cells grown under air-liquid interface would
Figure 3. Induction of soluble mediator release by the asthmatic and normal bronchial epithelial cells in response to EGF
stimulation. In Mod/Sev asthmatics (n= 11 patients), a significant induction of all four pro-inflammatory cytokines was seen, whilst in MA subjects
(n=8 patients), three of four mediators were induced; in the HC subjects (n=9 donors), only two mediators were induced significantly. Linear
contrast testing did not show any disease related trend in mediator production.
doi:10.1371/journal.pone.0072502.g003
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Figure 4. Characterization of neutrophil chemotactic and anti-apoptotic activity in PBEC-CM from Mod/Sev asthmatics. A)
Neutralizing monoclonal antibodies (mAb) against TNF-a or GM-CSF (100 mg/ml or their isotype-matched IgG controls) and the CXCR2 antagonist, SB-
225002 (100 nM) did not affect basal-CM (open bars) or EGF-CM- (solid bars) mediated neutrophil migration (n= 8 donors). (B) In neutrophil apoptosis
studies, neutralization of GM-CSF activity alone or in combination with TNF-a or IL-6R blockade inhibited basal-CM and EGF-CM-induced survival
(n=7 donors). Data represent mean 6 SEM analysed using repeated one-way ANOVA with post-hoc Bonferroni correction.
doi:10.1371/journal.pone.0072502.g004
Figure 5. Activation of class I PI(3)Ks during neutrophil chemotaxis and survival induced by PBEC-CM from Mod/Sev asthmatics. (A)
Pretreatment of neutrophils with wortmannin (100 nM, 30 min; solid bars) inhibited both basal-CM and EGF-CM-induced migration compared with
non-drug treated controls (p = 0.011 and p= 0.001, respectively), whilst the PI(3)Kc-selective inhibitor, AS-252424 (30 mM, 30 min; darker shaded bars)
significantly blocked EGF-CM-mediated chemotaxis (p = 0.021) (n=8 donors). (B) Both basal-CM and EGF-CM–induced neutrophil apoptosis were
markedly inhibited by LY294002 (30 mM; solid bars), but the PI(3)Kc (AS-252424, 30 mM) and d (IC87114, 10 mM; hatched bars)-selective inhibitors were
partially effective (n=9 donors). Data are mean 6 SEM and statistical significance by Mann-Whitney test, **p,0.01 and ***p,0.001 vs. non-drug
treated neutrophils.
doi:10.1371/journal.pone.0072502.g005
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have been potentially valuable. This would have required
identification of the most appropriate insult(s) (physical or
chemical) that results in a dysregulated injury-repair process seen
in asthma in vivo and this was beyond the scope of this manuscript.
Thus, further studies investigating the potential neutrophil-
modulatory capacity of pseudostratified epithelial cells established
from asthmatic patients are needed.
The Rho family of small GTPases is a central regulator of the
actin cytoskeleton in neutrophils during cell migration [53].
Selective inhibition of the HMG-CoA reductase by inhibitors,
such as mevastatin, blocks the downstream biosynthesis of
isoprenoid lipids, thus impairing RhoA GTPase membrane
targeting/activation and consequent neutrophil-airway epithelial
interactions [53,54]. In agreement with this, we have found that
blocking RhoA GTPase signaling in neutrophils with mevastatin
led to a marked reduction of both basal-CM and EGF-CM–
stimulated chemoattraction, suggestive of an involvement of RhoA
signaling in the neutrophil chemotactic response.
Class I PI(3)Ks regulate leukocyte recruitment, activation and
survival through the generation of PtdIns(3,4,5)P3 and are
subdivided into class IA (PI(3)Ka, PI(3)Kb and PI(3)Kd) and class
IB (PI(3)Kc) [41]. However, how the different isoforms of these
PI(3)Ks regulate epithelium-mediated neutrophil responses in
clinical asthma is unknown. We focused our studies on the role
of the myeloid-restricted PI(3)K c and d isoforms because of their
proposed role in lung inflammation in vivo [33,34,35,36]. Using a
pharmacological approach to inactivate the catalytic domain of
the p110c, we demonstrated that PBEC-CM-mediated neutrophil
migration was largely PI(3)Kc-dependent (,63%). Our findings
are in agreement with previous studies using murine PI(3)Kc
knockouts and PI(3)Kc selective inhibitors describing a major
dependence upon class IB PI(3)Kc signaling in neutrophil
recruitment [39,40,55], particularly during pulmonary inflamma-
tion in vivo [33,34,56]. However, given the species (and tissue)
differences and the inciting stimulus, it is important to exercise
caution in translating observations from animal models to human
clinical disease. For example, whereas primed oxidative burst in
murine neutrophils is largely dependent on PI(3)Kc alone, a
biphasic control of both PI(3)Kc and d activation is required in
regulating PtdIns(3,4,5)P3 signaling and consequent superoxide
generation in human neutrophils [42]. This highlights the need to
apply human-based ex vivo model systems to better understand
PI(3)K signaling mechanisms in the disease context in order to
develop isoform-selective anti-inflammatory therapeutics. In con-
trast, complete inhibition of neutrophil survival effect, (attributable
in part to, GM-CSF, Fig 4B) was possible only with the non-
selective PI(3)K inhibitor, LY294002, whereas the mono-selective
c and d inhibitors were only partially effective. This suggests some
functional redundancy amongst the PI(3)Ks in transducing the
PBEC-CM mediated pro-survival signals. Consistent with this
notion, pharmacological inhibition of at least three class I PI(3)K
isoforms was shown to be required effectively to block GM-CSF-
mediated survival effect in circulating neutrophils derived from
both healthy individuals and acutely exacerbated patients with
chronic obstructive pulmonary disease (COPD) [57].
The PI(3)Kd-selective inhibitor, IC87114 failed to block
neutrophil migration mediated by PBEC-CM from Mod/Sev
asthmatics. This is consistent with results in chemokine and
oxidants/cigarette smoke-induced neutrophil recruitment into the
bronchoalveolar space in models of acute lung inflammation
where IC87114 (or PI(3)Kd-dead knock-in mice) was shown to be
similarly ineffective when applied alone [34,58,59]. Given the
possibility of functional redundancy of class I PI(3)Ks signaling in
immune cells, one potential explanation is that PI(3)Kd may play a
more active role in driving the allergic-type inflammatory
responses than independently regulating neutrophilic recruitment
to inflammatory foci. Consistent with this notion, several pre-
clinical studies using genetic and pharmacological inactivation of
p110d have described an isoform-specific role for PI(3)Kd in
regulating mast cell activation and degranulation [60], allergen-
induced Th2 cytokine production and eosinophil recruitment into
the inflamed airways in vivo [35,36,61] – immunological responses
that are reminiscent of allergic asthma in humans [62]. In
addition, significantly higher levels of PI(3)K 110d mRNA
expression (but not p110c) are elevated in primary airway
smooth muscle cells derived from patients with mild/moderate
asthma compared to the non-asthmatic donors [63]. Of clinical
relevance, a phase I clinical trial for an inhaled PI(3)Kd-selective
inhibitor is currently being undertaken to establish proof of
mechanism in allergic asthma (http://clinicaltrials.gov/ct/show/
NCT01462617), whilst CAL-101 (an analogue of IC87114) is
being tested in patients with allergic rhinitis (http://clinicaltrials.
gov/ct2/show/NCT00836914).
Our study has some limitations. Although the observed anti-
apoptotic activity of the bronchial epithelial cells may prolong
neutrophil survival, it is possible that alternative cell death
Figure 6. Regulation of RhoA GTPase during neutrophil chemotaxis and survival mediated by PBEC-CM from Mod/Sev asthmatics.
(A) Pre-treatment of neutrophils with mevastatin (50 mM for 30 min; solid bars) attenuated both basal-CM and EGF-CM-mediated chemoattraction
compared with the non-drug treated controls (p = 0.047 and p=0.012, respectively). Vehicle-treated control cells were treated with 0.1% v/v DMSO
(n=5 donors). (B) Mevastatin did not affect basal-CM mediated neutrophil anti-apoptosis but partially inhibited EGF-CM-induced survival (p = 0.038)
(n=6 donors). Data represent mean 6 SEM and statistical significance by paired t-test *p,0.05 vs. non-drug treated neutrophils.
doi:10.1371/journal.pone.0072502.g006
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programmes exist that are independent of apoptosis. Recent work
has demonstrated non-apoptotic cell death pathways, such as
oncosis/necrosis [64,65], pyroptosis [65], cytolysis [66], NETosis
[67] and autophagic-like neutrophil death mechanisms [68] that
play important physiological roles in regulating neutrophil life-
span. In addition, the use of unprimed, blood-derived neutrophils
from healthy donors raises the question of whether chemotactic
and survival responses of neutrophils from asthmatic subjects
might be different. However, neutrophil preparations from
asthmatic patients often contain eosinophils and there is no
purification method which can selectively deplete these granulo-
cytes without priming/activating them. This study could have also
applied molecular approaches to block the pro-neutrophil
activities. However, we chose a direct, cytokine-neutralising
approach to therapeutically mimic the anti-cytokine biologics that
are currently undergoing clinical trials in uncontrolled severe
asthma [69].
In conclusion, we have identified a potentially important
regulatory mechanism whereby epithelial cells from patients with
asthma, stimulated by EGF, a key regulator of airway mucosal
pathobiology in asthma, influence neutrophil accumulation,
possibly involving class IB PI(3)Kc isoform signaling. The pro-
survival activity for neutrophils increases with asthma severity,
with evidence of GM-CSF playing a role and signaling via multiple
class I PI(3)Ks in neutrophils. These data highlight the important
functional regulation of class I PI(3)K isoforms in neutrophil
function, with implications for the development of selective anti-
inflammatory therapeutics for more severe forms of asthma.
Supporting Information
File S1 Supporting Methods. Figure S1, Shows that the PI
(3)Kd-selective inhibitor, IC87114, (10 mM; solid bars) did not
significantly (one way ANOVA, p= 0.16) affect either basal-CM
and EGF-CM-directed neutrophil chemotaxis compared with the
corresponding non-drug treated controls. Vehicle-treated control
cells were treated with DMSO (0.1% v/v). Neutrophil chemotaxis
was assessed using calcein-loaded cells in a fluorescence-based
chemotaxis microplate. Data represent mean6 SEM from PBECs
derived from n=6 different Mod/Sev asthma patients and using
peripheral-blood neutrophils from healthy subjects each per-
formed in duplicate. Figure S2, Schematic representation of
potential regulation of neutrophil chemotactic and anti-
apoptotic responses by an EGF-conditioned asthmatic
epithelium. Unresolved airway neutrophilia and disordered
airway epithelial function are pathobiological features in more
severe forms of asthma. It is proposed that an EGF-conditioned
asthmatic epithelium modulates neutrophil migration via a
potential signaling mechanism involving RhoA and class IB PI
(3)Kc signaling. EGF-conditioned epithelium also delays neutro-
phil constitutive apoptosis through the production of GM-CSF
and via activation of all class I PI (3)Ks in neutrophils. Table S1,
Comparability of the absolute values representing
neutrophil chemotactic and anti-apoptotic activity gen-
erated by PBEC-CM derived from patients with mild
asthma, Mod/Sev asthma and healthy controls. Sup-
porting References.
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